MedTrace Logo

The Avastin vs Visudyne for Neovascular AMD Study

NCT00390026 · Status: WITHDRAWN · Phase: PHASE3 · Type: INTERVENTIONAL

Last updated 2024-01-31

No results posted yet for this study

Summary

The object of the study is to compare the treatment effect of bevacizumab (Avastin), an antibody targeting vascular endothelial growth factor, with verteporfin photodynamic therapy (PDT) for patients with neovascular age-related macular degeneration, the leading cause of vision severe loss in the Western world.

Conditions

  • Age-related Macular Degeneration

Interventions

DRUG

Bevacizumab (Avastin)

DRUG

Verteporfin photodynamic therapy (PDT)

Sponsors & Collaborators

  • St. Erik Eye Hospital

    lead OTHER

Principal Investigators

  • Anders Kvanta, MD, PhD · S:t Erik's Eye Hospital

  • Stefan Seregard, MD, PhD · S:t Eriks Eye Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-11-30
Primary Completion
2008-11-30
Completion
2008-11-30

Countries

  • Sweden

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00390026 on ClinicalTrials.gov